Related Experiment Video
Updated: Sep 2, 2026

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
Published on: November 26, 2018
Haemodynamic effects of selective venoconstriction with centhaquine in spontaneously breathing patients with mixed
Athanasios Chalkias1,2,3, Aman Khanna4, Krish Vaidya5
1Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract:
Circulatory shock remains difficult to manage because fluid resuscitation and catecholamines may exacerbate vascular dysfunction and tissue hypoperfusion. This prospective physiological analysis, embedded within a multicentre phase IV study, examined whether selectively targeting the venous circulation with centhaquine improves circulatory dynamics in spontaneously breathing patients with mixed hypovolaemic-vasodilatory shock (MHVS). Fifteen spontaneously breathing adults with MHVS received centhaquine (0.01 mg kg-1) in addition to standard care. Over 300 min, mean circulatory filling pressure analogue increased from 6.03 ± 0.22 to 7.28 ± 0.21 mmHg and driving pressure for venous return from 5.88 ± 0.22 to 7.16 ± 0.21 mmHg (adjusted P < 0.001 for both), while estimated central venous pressure remained near atmospheric pressure and resistance to venous return remained unchanged. Cardiac output increased from 5.62 ± 0.22 to 6.80 ± 0.24 L min-1 and mean arterial pressure from 56.8 ± 1.5 to 69.8 ± 2.0 mmHg (adjusted P < 0.001 for both). Effective arterial elastance and systemic vascular resistance did not significantly change over time. Patients received 677 ± 79 mL of crystalloids during the study period, and no drug-related adverse events were observed. The findings of this preliminary physiological study suggest that selective venoconstriction may augment venous return and systemic haemodynamics in spontaneously breathing patients with MHVS without evidence of major adverse haemodynamic effects.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: β-Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

